longevityGraveyard archive2017–2024

AgeX Therapeutics

AgeX Therapeutics was one of the very few public companies built explicitly to reverse human aging with cellular reprogramming, and it disappeared not with a clinical flameout but with a quiet corporate vanishing act. Spun out of BioTime (later Lineage Cell Therapeutics) in 2017 under stem-cell pioneer Michael D. West, and listed on the NYSE American in November 2018 at a market capitalization around $138 million, AgeX carried marquee longevity science — its induced Tissue Regeneration (iTR) partial-reprogramming platform and PureStem pluripotent stem-cell technology — plus a marquee backer in Jim Mellon's Juvenescence. But it was never funded to match the ambition.

Years active

2017–2024

Peak valuation

$138M

Peak headcount

50

A stem-cell pioneer's second act

AgeX was the vehicle for Michael D. West, one of the field's foundational figures — he had founded Geron in 1990 and later ran Advanced Cell Technology, chasing telomerase, embryonic stem cells, and cloning long before 'longevity' was a fundable category. Incubated inside BioTime (which West also led) and formally organized in 2017, AgeX was built around two big ideas: PureStem, a system for deriving reproducible panels of purified human cell types from telomerase-positive pluripotent stem cells, and induced Tissue Regeneration (iTR), a partial-reprogramming approach meant to reawaken the body's latent capacity to regrow tissue. It was, on paper, a pure-play bet that you could manufacture youthful cells and switch regeneration back on.

Public, and underfunded, from the start

AgeX reached the public markets the hard way: rather than a cash-raising IPO, BioTime distributed AgeX shares to its own holders and AgeX began trading on the NYSE American on November 28, 2018 under the ticker AGE. The stock briefly flirted with $6 before settling around $3.85, a market capitalization near $138 million. Jim Mellon — the British financier who had made 'longevity investing' a public thesis with his book Juvenescence — was in from the beginning, and his firm Juvenescence quickly became the anchor, taking a large equity stake and, crucially, becoming AgeX's lender of last resort. From day one the company's science outran its balance sheet, and it leaned on Juvenescence loans to keep the lights on.

Living on loans

AgeX never generated meaningful revenue and never raised the kind of capital a reprogramming-and-cell-manufacturing platform needed to reach the clinic. Through 2019–2023 it functioned as a thinly traded micro-cap, organizing its aging portfolio into subsidiaries — ReCyte Therapeutics for regenerative cell products and Reverse Bioengineering for the iTR intellectual property — while its debt to Juvenescence steadily accumulated. The problem was structural rather than scientific: a small, public, pre-clinical aging company in a market with no appetite for decades-long timelines had almost no path to the money it required, and its largest shareholder was also its creditor.

The reverse merger and the disappearing assets

The end came as financial engineering. On March 26, 2024, AgeX completed a reverse merger into Serina Therapeutics, a private company developing a POZ-polymer drug-delivery platform. But the deal that took AgeX public-by-proxy also stripped it of its reason for existing: immediately before closing, substantially all of AgeX's legacy aging assets — its interests in ReCyte and Reverse Bioengineering and the iTR IP — were transferred into a newly created vehicle, UniverXome Bioengineering, which assumed AgeX's indebtedness. The surviving public company took the Serina Therapeutics name and ticker and refocused entirely on drug delivery, not aging.

Sold for its debt

In December 2024 Juvenescence acquired UniverXome — the vehicle now holding the old AgeX aging science — a move that let Serina retire roughly $11.2 million of debt and 'become debt-free,' as the transaction was framed. In practical terms, the longevity assets that had been AgeX's entire premise ended up back with the private backer that had been funding the company all along, while the public shell moved on to an unrelated business. There was no dramatic trial failure and no scandal; AgeX simply proved that being public was not the same as being capitalized. Its science survived, split off into private hands, but AgeX Therapeutics as an independent aging company was over — a cautionary tale about how a thinly funded longevity pioneer can be absorbed into someone else's business plan and quietly cease to exist.

What worked, what broke

What worked

Became one of the only publicly traded companies built explicitly around cellular reprogramming and induced tissue regeneration for human aging, listing on the NYSE American in November 2018.
Was led by Michael D. West, a foundational figure in the field who had earlier founded Geron and run Advanced Cell Technology, lending the venture unusual scientific pedigree.
Built two distinct platforms — PureStem for manufacturing purified human cell types from pluripotent stem cells, and induced Tissue Regeneration (iTR) for partial reprogramming to restore regenerative capacity.
Attracted Jim Mellon and Juvenescence as anchor backers, tying the company to one of the most visible longevity-investing franchises of its era.
Reached a public-market capitalization of roughly $138 million at spinout, giving cellular-rejuvenation science a rare listed vehicle.

What broke

Chronic undercapitalization: AgeX went public via share distribution rather than a cash-raising IPO and never secured the large-scale funding a pre-clinical reprogramming and cell-manufacturing platform required.
Total dependence on a single backer that was also its creditor — Juvenescence kept AgeX alive with loans, leaving the company structurally beholden to one shareholder's balance sheet.
No revenue and no near-term clinical catalyst, leaving a thinly traded micro-cap with no way to attract fresh capital in a market impatient with decades-long timelines.
The March 2024 Serina reverse merger stripped out substantially all of AgeX's aging assets into the UniverXome vehicle, converting the public company into an unrelated drug-delivery business.
The final sale of UniverXome to Juvenescence in December 2024 to clear roughly $11.2 million of debt returned the longevity science to its private backer and ended AgeX as an independent aging company.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network